Update: Advancing with fresh intent
Verisante has made progress on a number of fronts in the development of its laser Raman spectroscopy (LRS) products. Letters of intent have been signed with potential strategic partners in China and Poland over the global development and commercialisation of Core, an LRS-based diagnostic aid for assessing internal cancers (eg lung, GI). Meanwhile, discussions with the FDA over the appropriate regulatory pathway (de novo 510k/PMA) to seek approval for Aura, a skin cancer diagnostic probe, have begun and clarity is expected in the coming months.Verisante Technology is a medical device company engaged in the business of commercializing innovative systems for the early detection of cancer. Co. has licensed the exclusive world-wide rights to a technology developed by the BC Cancer Agency and the University of British Columbia and refined and tested at the Skin Care Centre at Vancouver General Hospital, for in vivo, real-time, non-invasive skin lesion measurements for the detection of skin cancer. The device, Verisante Aura™, can be used for the detection of all major forms of skin cancer, including basal cell carcinoma, squamous cell carcinoma, melanoma, and a pre-cancerous lesion, actinic keratosis.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.